login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

First patient enrolled in SCAFFOLD clinical study for carotid stenting


Thursday, 12 Sep 2013 10:09
Claudio Schönholz
Claudio Schönholz

Gore has announced that it has enrolled the first patient in its Carotid stent clinical study for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy (SCAFFOLD). The patient was successfully treated by Claudio Schönholz and his team at the Medical University of South Carolina in Charleston, USA.


“The first procedure using the Gore carotid stent was successful and the patient is doing well, having left the hospital the next day. Studies like this will further our understanding of optimal patient outcomes in carotid artery stenosis,” Schönholz said. “The new Gore device is designed to be flexible, offer plaque retention and stabilisation benefits, and along with bound heparin may provide advantages for improved patient outcomes.”

SCAFFOLD is a multicentre, single-arm, prospective study comparing the Gore carotid stent to a performance goal developed from carotid endarterectomy outcomes. The investigational study will include up to 50 sites in the US and will enrol approximately 312 patients. Co-principal investigators are Peter Schneider, Kaiser Permanente Medical Center, Honolulu; and William Gray, Columbia University Medical Center, New York.

“In times of uncertainty regarding optimal treatment for patients with high surgical risks, it is important to evaluate unique treatment options,” said Schneider.

Leveraging more than 35 years of clinical experience with expanded polytetrafluoroethylene (ePTFE), the Gore carotid stent is a next-generation device designed to integrate innovative material to trap arterial plaque against the vessel wall, while yielding maximised flexibility of the stent in order to conform to the often tortuous anatomy of carotid vasculature. The new Gore device combines the flexible properties of a traditional open-cell, nitinol stent design with a 500 micron pore size ePTFE lattice which offers the plaque retention and stabilisation benefits traditionally seen in a closed cell stent design. Additionally, the permanently bound heparin may offer a local advantage seen with other Gore devices that utilise bound heparin.

“Gore is committed to continuing development of innovative solutions for patients in order to improve their quality of life,” said Ben Beckstead, associate with the Gore Medical Division Peripheral Interventional Business. “The Gore SCAFFOLD clinical study will bring us one step closer to a new solution for improving patient outcomes, while simultaneously generating data for consideration of Medicare reimbursement for such procedures.”




Add New Comment

Related Items


Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

MR CLEAN: Better outcomes with intervention in ischaemic stroke patients
Thursday, 18 Dec 2014
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in ... MR CLEAN: Better outcomes with intervention in ischaemic stroke patients

Silk Road Medical unveils data from the ROADSTER trial
Wednesday, 26 Nov 2014
Silk Road Medical’s 30-day outcomes from the ROADSTER IDE study were presented at the Late Breaking Clinical Trials Session at the 2014 Vascular InterVentional Advances Meeting in Las Vegas, with ... Silk Road Medical unveils data from the ROADSTER trial

Features


Impact“ful” moments
Friday, 05 Dec 2014
Once a year, in almost ritualised fashion, the editors of peer-reviewed journals anxiously await publication of the Thomson Reuters Impact Factor. Journals in the “neuro” space are no exception to ... Impact“ful” moments

The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions